Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 10/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137923 | 0.88 | MTOR (0.37) | PRMT5PDE2AMTORPIK3CAPRKDC | |
| SCHEMBL20138177 | 0.82 | MAPT (0.38) | MAPTCYP11B1 | |
| SCHEMBL20138147 | 0.78 | MAPK1 (0.44) | MTOR | |
| SCHEMBL20137959 | 0.76 | RAB9A (0.37) | MAPT | |
| SCHEMBL20138283 | 0.76 | BACE1 (0.35) | PDE2AMTOR | |
| SCHEMBL18305069 | 0.76 | GRM2 (0.40) | MTOR | |
| SCHEMBL18304989 | 0.72 | PIK3CA (0.35) | PDE2AMTORPIK3CA | |
| SCHEMBL20138184 | 0.71 | MAPT (0.36) | MTORMAPT | |
| SCHEMBL20138155 | 0.70 | CYP11B1 (0.34) | MTORCYP11B1 | |
| SCHEMBL20138135 | 0.69 | GRM2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107873031-B | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | PRMT5 4853/4885PDE2A 766/4885MTOR 3479/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | PRMT5 4798/4885PDE2A 571/4885MTOR 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.